Aspira Women’s Health Inc. ( (AWHL) ) has released its Q3 earnings. Here is a breakdown of the information Aspira Women’s Health Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aspira Women’s Health Inc. is a company specializing in AI-enhanced bio-analytics for noninvasive gynecologic disease diagnostics and management tools, primarily focusing on ovarian cancer risk assessment. In its third-quarter 2025 financial report, Aspira announced stable product revenues of $2.3 million, with a notable 7% increase in the average unit price per test. The company has undergone significant strategic shifts, emphasizing relationships with large healthcare systems and focusing on profitable revenue growth over volume. Key financial metrics for the nine months ending September 30, 2025, include a 9.3% increase in average unit price, a 12.2% rise in gross profit, and a 34% reduction in operating expenses. Aspira also reported a 54.5% reduction in cash used for operations, reflecting improved cost control and productivity. Looking forward, Aspira’s management remains optimistic about continued efficiency improvements and long-term profitability, with ongoing emphasis on strategic partnerships and innovation in diagnostic tools.